Anne Fabienne Weitsch
Geen lopende functies
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Michel Vandevelde | M | - |
H-Phar NV
H-Phar NV Pharmaceuticals: MajorHealth Technology H-PHAR SA was founded in 2002 to develop products based on Hubriphar SA 'Know How', in particular, a drug (Azodicarbonamide) inactivating the retroviral nucleocapside Protein 7 (NCp7) opening a new therapeutic route to treat mutated HIV resistant to the actual therapy combining at least three active medicinal products. H-Phar is a pharmaceutical research company that develops candidate drugs based on its own worldwide patented technology. Through, knowledge, creativity and integrity, H-Phar aims to preserve and improve human health by offering treatments to everyone everywhere. H-Phar is active in four operating areas include preclinical research focusing on the development of anti-viral applications of the so-called 'zinc finger ejector' in the domain of hemorrhagic fever (arenaviruses) and oncoviruses (HPV**), preclinical research focusing on the development of immune-modulator drugs inhibiting graft rejection, clinical development of an anti-HIV*drug based on a totally new mechanism of action, Vaccine evaluation of a dendritic cell loaded with HPH116 killed virus vaccine for immunological responses boost. H-Phar studies are compliant with OCDE Guidelines and ICH/GMP/GLP/GCP rules. H-Phar has build partnerships with opinion leaders in major institutions in Belgium, Europe and the US. | 9 jaar |
Hélène Margery | F | - |
H-Phar NV
H-Phar NV Pharmaceuticals: MajorHealth Technology H-PHAR SA was founded in 2002 to develop products based on Hubriphar SA 'Know How', in particular, a drug (Azodicarbonamide) inactivating the retroviral nucleocapside Protein 7 (NCp7) opening a new therapeutic route to treat mutated HIV resistant to the actual therapy combining at least three active medicinal products. H-Phar is a pharmaceutical research company that develops candidate drugs based on its own worldwide patented technology. Through, knowledge, creativity and integrity, H-Phar aims to preserve and improve human health by offering treatments to everyone everywhere. H-Phar is active in four operating areas include preclinical research focusing on the development of anti-viral applications of the so-called 'zinc finger ejector' in the domain of hemorrhagic fever (arenaviruses) and oncoviruses (HPV**), preclinical research focusing on the development of immune-modulator drugs inhibiting graft rejection, clinical development of an anti-HIV*drug based on a totally new mechanism of action, Vaccine evaluation of a dendritic cell loaded with HPH116 killed virus vaccine for immunological responses boost. H-Phar studies are compliant with OCDE Guidelines and ICH/GMP/GLP/GCP rules. H-Phar has build partnerships with opinion leaders in major institutions in Belgium, Europe and the US. | 9 jaar |
Chong Kiat Lim | M | 68 |
University of Cambridge
| 7 jaar |
Gregory Winter | M | 73 |
University of Cambridge
| 7 jaar |
Robert J. West | M | - |
University of Cambridge
| 6 jaar |
Gareth Beynon | M | - |
University of Cambridge
| 6 jaar |
Adam C. Baker | M | - |
University of Cambridge
| 5 jaar |
Belita S. Ong | F | - |
University of Cambridge
| 4 jaar |
Luc Jean Edouard Argand | M | 76 |
University of Geneva
| 4 jaar |
Jean-Luc Herbez | M | - |
University of Geneva
| 8 jaar |
Angus Porter | M | 67 |
University of Cambridge
| 4 jaar |
Michael John Wilson | M | - |
University of Cambridge
| 8 jaar |
Steve Young | M | - |
University of Cambridge
| 7 jaar |
Mike Gunn | M | - |
University of Cambridge
| 9 jaar |
Joanna Mary Gordon Perry | F | 67 |
University of Cambridge
| 3 jaar |
James Edward Smith | M | 71 |
University of Cambridge
| 3 jaar |
Steve M. Hobbs | M | - |
University of Cambridge
| 4 jaar |
John Katsaounis | M | - |
University of Geneva
| 4 jaar |
Francis McCormick | M | 73 |
University of Cambridge
| 3 jaar |
Dominique Rochat | M | 75 |
University of Geneva
| 3 jaar |
Andrew Unitt | M | 66 |
University of Cambridge
| 4 jaar |
Philip Atkin | M | - |
University of Cambridge
| 4 jaar |
David Waimann | M | - |
University of Cambridge
| 3 jaar |
Brij Mohan Tirath R. Kataria | M | - |
University of Cambridge
| 1 jaar |
Peter Highfield | M | - |
University of Cambridge
| 4 jaar |
Anthony Mark Savill | M | - |
University of Cambridge
| 3 jaar |
David Harrison | M | - |
University of Cambridge
| 1 jaar |
Nigel Smethers | M | - |
University of Cambridge
| 4 jaar |
Richard Burnett-Hall | M | - |
University of Cambridge
| 1 jaar |
Jörg Buchmüller | M | 76 |
University of Geneva
| 1 jaar |
Paul Young | M | 68 |
University of Cambridge
| 4 jaar |
Paul Hanworth | M | - |
University of Cambridge
| 3 jaar |
Tony H. J. Quick | M | 68 |
University of Cambridge
| 3 jaar |
Martin Smith | M | - |
University of Cambridge
| 7 jaar |
John Buchanan | M | 72 |
University of Cambridge
| 4 jaar |
Krishna N Ganesh | M | - |
University of Cambridge
| 3 jaar |
Nigel Keith Anthony Standish Vaz | M | 67 |
University of Cambridge
| 4 jaar |
Mark Wainwright Todd | M | 69 |
University of Cambridge
| 4 jaar |
Robert Gresham Gray | M | 70 |
University of Cambridge
| 4 jaar |
John Ryding | M | - |
University of Cambridge
| 4 jaar |
Dominique Amaudruz Guiramand | F | 70 |
University of Geneva
| 3 jaar |
Steven C. Schroer | M | - |
University of Cambridge
| 3 jaar |
Tong Boon Quek | M | 68 |
University of Cambridge
| 4 jaar |
Jean-Claude E. Gehret | M | 76 |
University of Geneva
| 3 jaar |
Ilan Hayim | M | 73 |
University of Geneva
| 4 jaar |
Hwee Hua Lim | F | 65 |
University of Cambridge
| 4 jaar |
Alan Colman | M | 75 |
University of Cambridge
| 3 jaar |
Alexandre Davidoff | M | - |
University of Geneva
| 3 jaar |
Mohamed Ibrahim Mahmoud Mohamed | M | 90 |
University of Geneva
| 3 jaar |
Philip Hanson | M | 67 |
University of Cambridge
| 4 jaar |
William Graham Cooper | M | 67 |
University of Cambridge
| 1 jaar |
Daniel Lew | M | 76 |
University of Geneva
| 3 jaar |
Jean-Pierre Pieren | M | 81 |
University of Geneva
| 4 jaar |
Patrick Mahy | M | - |
H-Phar NV
H-Phar NV Pharmaceuticals: MajorHealth Technology H-PHAR SA was founded in 2002 to develop products based on Hubriphar SA 'Know How', in particular, a drug (Azodicarbonamide) inactivating the retroviral nucleocapside Protein 7 (NCp7) opening a new therapeutic route to treat mutated HIV resistant to the actual therapy combining at least three active medicinal products. H-Phar is a pharmaceutical research company that develops candidate drugs based on its own worldwide patented technology. Through, knowledge, creativity and integrity, H-Phar aims to preserve and improve human health by offering treatments to everyone everywhere. H-Phar is active in four operating areas include preclinical research focusing on the development of anti-viral applications of the so-called 'zinc finger ejector' in the domain of hemorrhagic fever (arenaviruses) and oncoviruses (HPV**), preclinical research focusing on the development of immune-modulator drugs inhibiting graft rejection, clinical development of an anti-HIV*drug based on a totally new mechanism of action, Vaccine evaluation of a dendritic cell loaded with HPH116 killed virus vaccine for immunological responses boost. H-Phar studies are compliant with OCDE Guidelines and ICH/GMP/GLP/GCP rules. H-Phar has build partnerships with opinion leaders in major institutions in Belgium, Europe and the US. | - |
Geoffrey Hale | M | - |
University of Cambridge
| 3 jaar |
Hugh Nineham | M | - |
University of Cambridge
| 3 jaar |
Chris Hills | M | - |
University of Cambridge
| 4 jaar |
Gordon Cudmore | M | - |
University of Cambridge
| 3 jaar |
Desmond Radlein | M | 74 |
University of Cambridge
| 3 jaar |
Ian Metcalfe | M | 66 |
University of Cambridge
| 3 jaar |
Graham Keniston-Cooper | M | - |
University of Cambridge
| 4 jaar |
Mark Christopher Greaves | M | 67 |
University of Cambridge
| 4 jaar |
Guilherme Brafman | M | - |
University of Cambridge
| 3 jaar |
Jonathan Jones | M | - |
University of Cambridge
| 3 jaar |
Reyaz A. Ahmad | M | - |
University of Cambridge
| 5 jaar |
Pierre Francotte | M | 67 |
University of Cambridge
| 4 jaar |
Gerard Evan | M | - |
University of Cambridge
| 4 jaar |
Frank Christian Wignall | M | 68 |
University of Cambridge
| 4 jaar |
Timothy Norman Wallach | M | - |
University of Cambridge
| 4 jaar |
Paul Averback | M | 73 |
University of Cambridge
| 3 jaar |
David Turnbull | M | 69 |
University of Cambridge
| 4 jaar |
Massimo Giovanni Prelz Oltramonti | M | 70 |
University of Geneva
| 4 jaar |
Dominic Casserley | M | 67 |
University of Cambridge
| 4 jaar |
David Dew | M | 69 |
University of Cambridge
| 4 jaar |
Charles Baker | M | 66 |
University of Cambridge
| 4 jaar |
David Godden | M | - |
University of Cambridge
| 4 jaar |
Peter Bazalgette | M | 71 |
University of Cambridge
| 4 jaar |
Claude Messulam | M | 73 |
University of Geneva
| 1 jaar |
Andrew Tomlinson | M | - |
University of Cambridge
| 4 jaar |
Suet-Fern Lee | F | 66 |
University of Cambridge
| 3 jaar |
Bella Ann Almeida | F | 68 |
University of Cambridge
| 3 jaar |
David Sidwell | M | 71 |
University of Cambridge
| 4 jaar |
Didier Georges | M | - |
H-Phar NV
H-Phar NV Pharmaceuticals: MajorHealth Technology H-PHAR SA was founded in 2002 to develop products based on Hubriphar SA 'Know How', in particular, a drug (Azodicarbonamide) inactivating the retroviral nucleocapside Protein 7 (NCp7) opening a new therapeutic route to treat mutated HIV resistant to the actual therapy combining at least three active medicinal products. H-Phar is a pharmaceutical research company that develops candidate drugs based on its own worldwide patented technology. Through, knowledge, creativity and integrity, H-Phar aims to preserve and improve human health by offering treatments to everyone everywhere. H-Phar is active in four operating areas include preclinical research focusing on the development of anti-viral applications of the so-called 'zinc finger ejector' in the domain of hemorrhagic fever (arenaviruses) and oncoviruses (HPV**), preclinical research focusing on the development of immune-modulator drugs inhibiting graft rejection, clinical development of an anti-HIV*drug based on a totally new mechanism of action, Vaccine evaluation of a dendritic cell loaded with HPH116 killed virus vaccine for immunological responses boost. H-Phar studies are compliant with OCDE Guidelines and ICH/GMP/GLP/GCP rules. H-Phar has build partnerships with opinion leaders in major institutions in Belgium, Europe and the US. | - |
William Gilfillan Lamarque | M | 70 |
University of Cambridge
| 4 jaar |
Alastair K. Livesey | M | 67 |
University of Cambridge
| 4 jaar |
Clive Partridge | M | - |
University of Cambridge
| 4 jaar |
William Spurgin | M | - |
University of Cambridge
| 4 jaar |
Tony Alves | M | 62 |
University of Cambridge
| 4 jaar |
John David Porter | M | - |
University of Cambridge
| 4 jaar |
Jonathan E. Clegg | M | - |
University of Cambridge
| 4 jaar |
Beat W. Hess | M | 74 |
University of Geneva
| 3 jaar |
Lim Andy | M | 66 |
University of Cambridge
| 4 jaar |
John Bailey | M | - |
University of Cambridge
| 3 jaar |
Jonathan Charles Kingsman | M | 67 |
University of Cambridge
| 2 jaar |
Charles E. Forrest | M | - |
University of Cambridge
| 3 jaar |
Manu Bhaskaran | M | 66 |
University of Cambridge
| 4 jaar |
Peter Jackson | M | 62 |
University of Cambridge
| 4 jaar |
Fiona Claire Reynolds | F | 66 |
University of Cambridge
| 4 jaar |
Andrew Galazka | M | 69 |
University of Cambridge
| 3 jaar |
Richard Greer | M | - |
University of Cambridge
| 3 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 81 | 81.00% |
Zwitserland | 15 | 15.00% |
België | 4 | 4.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Anne Fabienne Weitsch
- Persoonlijk netwerk